LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Home・Aandelen Lijst・Cassava Sciences Inc

Cassava Sciences Inc

Gesloten

SectorGezondheidszorg

2.77 0.73

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.63

Max

2.82

Belangrijke statistieken
By Trading Economics
Inkomsten	-21M -44M
Winstmarge	-2,258.347
Werknemers	30
EBITDA	-21M -45M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+189.86% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	38M 146M
Vorige openingsprijs	2.04
Vorige sluitingsprijs	2.77

Nieuwssentiment

By Acuity

50%

185 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

1.56 / 1.7 Steun & Weerstand

Cassava Sciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 nov 2025, 18:59 UTC

Belangrijke Marktbewegers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Marktinformatie

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Marktinformatie

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Marktinformatie

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Winsten

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Winsten

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Marktinformatie

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Marktinformatie

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Acquisities, Fusies, Overnames

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Winsten

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Acquisities, Fusies, Overnames

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Marktinformatie

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Vergelijking

Prijswijziging

Cassava Sciences Inc Prognose

Koersdoel

By TipRanks

189.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD 189.86%

Hoogste 8 USD

Laagste 8 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cassava Sciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Cassava Sciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.56 / 1.7Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

185 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.